Abstracts tagged "Biologicals"

Abstract Number: 110 • 2023 Pediatric Rheumatology Symposium
Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Tania Watts¹, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne Benseler⁷ and Rae Yeung⁸, ¹Department of Immunology, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁴Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health; Department of Molecular Genetics, University of Toronto, Toronto, ON, ⁶Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Québec, Canada; Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁷Division of Rheumatology, Department of Paediatrics, The Alberta Children’s Hospital, Calgary, AB, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare antibody responses to COVID-19 vaccines among children with autoimmune diseases taking different classes of immunosuppressantsMethods: A prospective observational study was conducted at…
Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium
Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis
Alysha Taxter¹, Marc Natter², Min-Lee Chang², Laura Schanberg³, Valarie Morrow⁴, Eveline Wu⁵, Tedryl Bumpass⁴, Alex Fist⁴, Meg Waite⁶, Vincent Del Gaizo⁷, Melanie Kohlheim⁷ and CARRA Registry Investigators⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²Boston Children's Hospital, Boston, MA, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵UNC Chapel Hill, Chapel Hill, NC, ⁶Boston Children's Hospital, Boston, MA, ⁷CARRA, Washington, DC
Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…
Abstract Number: L07 • ACR Convergence 2022
Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study
Di Wu¹, Jing Li¹, Dong Xu¹, Li Wang¹, Jianmin Fang², Dan Ross³ and Fengchun Zhang⁴, ¹Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China, Beijing, China, ²Shanghai Tongji Hospital, Tongji University, Shanghai 200065, China School of Life Science and Technology, Tongji University, Shanghai 200092, China, Shanghai, China, ³RemeGen Co., San Diego, CA, ⁴Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, Beijing, China
Background/Purpose: Telitacicept is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor…
Abstract Number: L12 • ACR Convergence 2022
First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background
Remco Erkens¹, Rashmi Sinha², Alex Pickering³, Grant Schulert⁴, Alexei Grom⁴, Lars van der Veken¹, Hanneke van Deutekom¹, Jorg Calis¹, Jorg van Loosdregt⁵ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Systemic JIA Foundation, Cincinnati, OH, ³Systemic JIA Foundation, San Francisso, CA, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University Medical Center Utrecht, Wilhelmina Children's Hospital, Zeist, Netherlands
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a severe subtype of JIA. Recently, interstitial lung disease (SJIA-LD) has been reported as a severe complication of…
Abstract Number: 0245 • ACR Convergence 2022
Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD
Bryant England¹, Michael George², Yangyuna Yang¹, Punyasha Roul³, Jorge Rojas⁴, Brian Sauer⁵, Grant Cannon⁶, Joshua Baker⁷, Jeffrey Curtis⁸ and Ted Mikuls⁹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³UNMC, Omaha, NE, ⁴George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Salt Lake City VA, Salt Lake city, ⁷University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁸Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with RA-associated interstitial lung disease (RA-ILD) suffer from substantial morbidity and premature mortality. The optimal use of biologic/tsDMARDs in this population is poorly…
Abstract Number: 0350 • ACR Convergence 2022
Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
Vicente Aldasoro¹, María Laiño¹, Monica Enguita¹, Santos Castañeda², Javier Loricera³, Carmen Lasa-Teja⁴, Clara Moriano⁵, Vanesa Calvo Río⁶, Ivette Casafont-Solé⁷, Judit Font Urgelles⁷, Patricia Quiroga-Colina⁸, Samuel Hernandez⁹, Sergi Heredia¹⁰, A. Garcia-Aparicio¹¹, Joaquin Maria Belzunegui Otano¹², Aaron Fariña¹³, Francisco Javier Navarro Blasco¹⁴, Patricia Fanlo Mateo¹, Adela Gallego¹⁵, Juan M Blanco Madrigal¹⁶, María Ángeles Matías¹⁷, Cilia Peralta¹⁸, Jordi Camins-Fàbregas¹⁹, Marcos Paulino²⁰, Ana Urruticoechea²¹, Piter Jose Cossio Jimenez²², Miguel Medina Malone²³, Eva Perez Pampin²⁴, Rafaela Ortega-Castro²⁵, Blanca varas de Dios²⁶, Jose Ramon Lamua Riazuelo²⁷ and Emilio Jose Giner²⁸, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Complejo Asistencial Universitario de León, León, Spain, ⁶Valdecilla Hospital, Santander, Spain, ⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁹Hospital Son Llàtzer, Palma de Mallorca, Spain, ¹⁰Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despi, Spain, ¹¹Hospital Universitario de Toledo, Toledo, Spain, ¹²Hospital Universitario de Donostia, Donostia-San Sebasti, Spain, ¹³Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹⁴Hospital General Universitario de Elche, Elche, Spain, ¹⁵Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹⁶Basurto University Hospital, Bilbao, Spain, ¹⁷Hospital Universitario Infanta Leonor, Madrid, Spain, ¹⁸Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁹Hospital General de Granollers, Granollers, Spain, ²⁰Hospital General Universiario de Ciudad Real, Ciudad Real, Spain, ²¹Hospital Can Misses, Ibiza, Spain, ²²Hospital Reina Sofia, Tudela, Spain, ²³Hospital Calahorra, Calahorra, Spain, ²⁴Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Cordoba, Spain, ²⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²⁶Santa Cristina Hospital, Madrid, Spain, ²⁷Hospital Universitario del Henares, Madrid, Spain, ²⁸Hospital Royo Villanova, Zaragoza, Spain
Background/Purpose: To describe demographic characteristics, efficacy and safety of BLM since its approval in SLE patients in a real-world setting. Methods: Descriptive, retrospective, multicenter study…
Abstract Number: 0431 • ACR Convergence 2022
Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept
Ana Lúcia Martins Fernandes¹, Ana Pinto², Kalveer flora³, dilpreet matharu³, anthony isaacs³ and Pedro Machado⁴, ¹Centro Hospitalar Universitário do Algarve, Faro, Portugal, ²Local Health Unit of Guarda, Barcelos, Portugal, ³Northwick Park Hospital, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: Biotherapeutics have revolutionized the treatment of axial spondyloarthritis (axSpA). The emergence of biosimilars allowed substantial savings and a wider access to treatment, and international…
Abstract Number: 0779 • ACR Convergence 2022
Early Experience of Breakthrough COVID-19 Infections in Patients Who Received Pre-exposure Prophylaxis with Tixagevimab/cilgavimab
Cassandra Calabrese¹, Elizabeth Kirchner², alexandra villa forte², Rula Hajj-Ali³, Carol Langford⁴, james Fernandez², Alise Carlson², Brandon Moss², Vickie Sayles⁴, Andrea Pallotta², Alice kim² and Leonard Calabrese⁴, ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic, Hunting Valley, OH, ⁴Cleveland Clinic, Cleveland, OH
Background/Purpose: Patients receiving B cell depleting therapies (BCDT) for immune mediated inflammatory diseases (IMIDs) have high risk of poor COVID-19 outcomes and strategies for COVID-19…
Abstract Number: 0888 • ACR Convergence 2022
Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)
Nathalie Carrier¹, Sophie Roux², Hugues Allard-Chamard² and Gilles Boire³, ¹Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, ²Université de Sherbrooke and Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, ³Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Uncontrolled inflammation in rheumatoid arthritis (RA) patients increases the risk for incident Ischemic Heart Disease (IHD) and venous thromboembolic (TE) events. Reducing inflammation using…
Abstract Number: 1043 • ACR Convergence 2022
Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis
Jan Brandt-Juergens¹, Martin Rudwaleit², Frank Behrens³, Christopher Ritchlin⁴, Daniel Peterlik⁵, Erhard Quebe-Fehling⁶, Renato Calheiros⁷ and Atul Deodhar⁸, ¹Rheumatologische Schwerpunktpraxis, Berlin, Germany, ²University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ³Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁴Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corp., Hoboken, NJ, ⁸Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Uveitis is one of the most frequently reported extra-musculoskeletal manifestations of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).1,2 The prevalence of anterior uveitis is…
Abstract Number: 1407 • ACR Convergence 2022
Longitudinal Lipid Profile and NT-proBNP Changes from Pre-clinical to Established Rheumatoid Arthritis: A 12 Years Follow up Explorative Study
Reinder Raadsen¹, Laurette van Boheemen¹ and Michael Nurmohamed², ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk for developing cardiovascular diseases (CVD). This is partly due to the systemic inflammation characteristic to…
Abstract Number: 1564 • ACR Convergence 2022
Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involvement in Behçet’s Disease
Nuria Barroso-García¹, Belén Atienza-Mateo², Ivan Ferraz Amaro³, Diana Prieto-Peña², Ana De Vicente-Delmás⁴, Ricardo Blanco⁵ and Miguel Ángel González-Gay⁶, ¹Hospital Universitario Puerta del Mar, Cádiz, Spain, Cádiz, Spain, ²Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁴Hospital General Santa María del Puerto, Cádiz, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: To evaluate the efficacy of anti-TNF or anti-IL6 treatment in severe and refractory ocular involvement in patients with refractory cystoid macular edema (CME) due…
Abstract Number: 2001 • ACR Convergence 2022
Cardiovascular Risk Factors and Therapeutic Outcome in Rheumatoid Arthritis – Real World Data
Tanya Shivacheva, Medical University prof.dr. P. Stoyanov, Varna, Bulgaria, Varna, Bulgaria
Background/Purpose: Sustained targeted therapeutic outcome with biological therapy in real clinical conditions is not yet achievable in a large proportion of rheumatoid arthritis (RA) patients.…
Abstract Number: 2138 • ACR Convergence 2022
Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
BEATRIZ E. JOVEN¹, Concepción Fito Manteca², Enrique Rubio³, Enrique Raya Álvarez⁴, Alba Pérez⁵, Raquel Hernández⁶, Sara Manrique Arija⁷, Mercedes Núñez⁸, Silvia Díaz⁸, Luis Trancho⁸, Sebastian Moyano⁸, Alessandra Lacetera⁹, Noelia Alfaro-Oliver⁹ and Rosario Garcia-Vicuña¹⁰, ¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²Hospitalario de Navarra, Pamplona, Spain, ³Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁴Hospital Universitario San Cecilio, Granada, Spain, ⁵Hospital Puerta del Mar, Cádiz, Spain, ⁶Virgen de Valme University Hospital, Sevilla, Spain, ⁷Hospital Regional Universitario Málaga, Málaga, Spain, ⁸Lilly, Alcobendas, Spain, ⁹OXON Epidemiology, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
Background/Purpose: Interleukin-17A inhibitors (anti-IL17) have provided an additional treatment option in the management of the psoriatic arthritis (PsA). This study aims to describe the patient…
Abstract Number: 0259 • ACR Convergence 2022
Impact of Comorbidity on Disease Activity and Functional Status in Patients with Rheumatoid Arthritis Receiving Biologic DMARDs, a Longitudinal Analysis of the KOBIO-RA
Ju Yeon Kim¹, Kichul Shin², Eun Bong Lee¹ and Jun Won Park¹, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: This study aims to evaluate the impact of comorbidities on disease activity and functional disability in patients with RA treated with biological disease-modifying anti-rheumatic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].